20 March 2017

Posting of Annual report & Notice of AGM

RNS Number : 9721Z

Verona Pharma PLC

20 March 2017

 

 

 

Verona Pharma plc

("Verona Pharma" or the "Company") 

2016 Annual Report and Accounts

and

Notice of AGM

 

20 March 2017, London - Verona Pharma plc (AIM: VRP.L), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs, is pleased to confirm that a hard copy of the Annual Report and Accounts for the year ended 31 December 2016 ("2016 Annual Report and Accounts"), the Notice of Annual General Meeting and a Form of Proxy have been posted to Shareholders.

The Company confirms that its 2016 Annual Report and Accounts are available online at: http://www.veronapharma.com/investors/#investors-financial-performance. The Notice of Annual General Meeting can be found within the AIM Rule 26 section of the website.

The Annual General Meeting of Verona Pharma will be held at the offices of Shakespeare Martineau LLP, 6th Floor, 60 Gracechurch Street, London EC3V 0HR on 12th April 2017 at 12.00 noon.

-Ends-

 

For further information please contact:

Verona Pharma plc

Tel: +44 (0)20 3283 4200

Jan-Anders Karlsson, Chief Executive Officer

 

 

 

N+1 Singer

Tel: +44 (0)20 7496 3000

Aubrey Powell / James White/ Alex Laughton-Scott

 

 

 

FTI Consulting

Tel: +44 (0)20 3727 1000

Simon Conway / Stephanie Cuthbert / Natalie Garland-Collins

 

 

 

 

Notes to Editors

About Verona Pharma plc

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. 

Verona Pharma's product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti‑inflammatory agent in a single compound. In clinical trials, treatment with RPL554 has been observed to result in statistically significant improvements in lung function as compared to placebo and has shown clinically meaningful and statistically significant improvements in lung function when added to two commonly used bronchodilators as compared to either bronchodilator administered as a single agent. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis, and potentially asthma.

 

 

 


This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

MSCKMGZFFGMGNZM

For further information please contact:

 

Verona Pharma plc
Jan-Anders Karlsson, CEO
Tel: +44 (0)20 3283 4200
info@veronapharma.com

N+1 Singer (Nominated Adviser and UK Broker)
Aubrey Powell / James White
Tel: +44 (0)20 7496 3000

 

 

FTI Consulting
Simon Conway / Stephanie Cuthbert / Natalie Garland-Collins
Tel: +44 (0)20 3727 1000
veronapharma@fticonsulting.com

ICR, Inc. (US Media and Investor enquiries)
James Heins
Tel: +1 203-682-8251
James.Heins@icrinc.com

Stephanie Carrington
Tel. +1 646-277-1282
Stephanie.Carrington@icrinc.com


Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us